Literature DB >> 20554520

Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development.

Aninda Basu1, Dipak Datta, David Zurakowski, Soumitro Pal.   

Abstract

The high incidence of cancer and its aggressive progression is a common and major problem in patients receiving immunosuppressive therapy. The calcineurin inhibitors (CNIs) may have protumorigenic effects and can promote the overexpression of several molecules inducing tumor growth. We have recently demonstrated that CNIs can mediate the transcriptional activation of the angiogenic cytokine vascular endothelial growth factor (VEGF) and promote a rapid progression of human renal cancer. Here, we investigated whether the CNI cyclosporine (CsA) and the mTOR inhibitor rapamycin (RAPA) could alter the mRNA stability of VEGF in 786-0 and Caki-1 renal cancer cells. Following actinomycin D treatment, we observed that CsA increased, whereas RAPA decreased the VEGF mRNA stability as observed by real time PCR. It is established that the mRNA-binding protein HuR may play a critical role in VEGF mRNA stability. By using HuR-siRNA, we found that the knockdown of HuR significantly decreased the CNI-induced VEGF mRNA stability. By Western blot analysis, it has been observed that CNI treatment induced the translocation of HuR from the nucleus to the cytoplasm; CNIs also induced the association between HuR and PKC-delta and promoted the phosphorylation of HuR. Finally, we found that the inhibition of PKC-delta using a dominant negative plasmid significantly decreased the CsA-induced cytoplasmic translocation of HuR and VEGF mRNA stability. Together, targeting the pathways that promote CNI-induced transcription as well as the mRNA stability of VEGF might serve as novel therapeutics for the prevention and treatment of cancer in immunosuppressed patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554520      PMCID: PMC2919082          DOI: 10.1074/jbc.M110.119446

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways.

Authors:  Clifford S Cho; Johny Elkahwaji; Zheng Chang; Tara L Scheunemann; Eric R Manthei; Majed M Hamawy
Journal:  Cell Signal       Date:  2003-01       Impact factor: 4.315

2.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

Authors:  J Liu; J D Farmer; W S Lane; J Friedman; I Weissman; S L Schreiber
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

3.  Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.

Authors:  Dipak Datta; Alan G Contreras; Aninda Basu; Olivier Dormond; Evelyn Flynn; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

4.  Calcineurin: a calcium- and calmodulin-binding protein of the nervous system.

Authors:  C B Klee; T H Crouch; M H Krinks
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Cancer after kidney transplantation in the United States.

Authors:  Bertram L Kasiske; Jon J Snyder; David T Gilbertson; Changchun Wang
Journal:  Am J Transplant       Date:  2004-06       Impact factor: 8.086

6.  Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.

Authors:  Rami T Bustami; Akinlolu O Ojo; Robert A Wolfe; Robert M Merion; William M Bennett; Suzanne V McDiarmid; Alan B Leichtman; Philip J Held; Friedrich K Port
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

Review 7.  Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.

Authors:  Markus Guba; Christian Graeb; Karl-Walter Jauch; Edward K Geissler
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

8.  The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase.

Authors:  Jesse A Flaxenburg; Michael Melter; Peter H Lapchak; David M Briscoe; Soumitro Pal
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

9.  Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells.

Authors:  Ryuichiro Murakami; Fukushi Kambe; Hirohito Mitsuyama; Kenji Okumura; Toyoaki Murohara; Satoru Niwata; Ryohei Yamamoto; Hisao Seo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-09-04       Impact factor: 8.311

10.  Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.

Authors:  Gudrun E Koehl; Joachim Andrassy; Markus Guba; Sebastian Richter; Alexander Kroemer; Marcus N Scherer; Markus Steinbauer; Christian Graeb; Hans J Schlitt; Karl-Walter Jauch; Edward K Geissler
Journal:  Transplantation       Date:  2004-05-15       Impact factor: 4.939

View more
  19 in total

1.  Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.

Authors:  Aninda Basu; Pallavi Banerjee; Soumitro Pal
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

2.  Increased synthesis of folate transporters regulates folate transport in conditions of ethanol exposure and folate deficiency.

Authors:  Shilpa Thakur; Deepti More; Beenish Rahat; Krishan Lal Khanduja; Jyotdeep Kaur
Journal:  Mol Cell Biochem       Date:  2015-10-03       Impact factor: 3.396

3.  Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.

Authors:  Aninda Basu; Tao Liu; Pallavi Banerjee; Evelyn Flynn; David Zurakowski; Dipak Datta; Ondrej Viklicky; Martin Gasser; Ana Maria Waaga-Gasser; Jun Yang; Soumitro Pal
Journal:  Cancer Lett       Date:  2012-02-14       Impact factor: 8.679

4.  Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.

Authors:  Elizabeth Van Tubergen; Robert Vander Broek; Julia Lee; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Keith L Kirkwood; Nisha J D'Silva
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

5.  TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR).

Authors:  Anna Goc; Mrunal Choudhary; Tatiana V Byzova; Payaningal R Somanath
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

6.  Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma.

Authors:  Naoshad Muhammad; Sourav Bhattacharya; Robert Steele; Nancy Phillips; Ratna B Ray
Journal:  Clin Cancer Res       Date:  2016-12-13       Impact factor: 12.531

7.  Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.

Authors:  Craig B Woda; Sarah Bruneau; Anne Linde Mak; Zdenka Haskova; Kaifeng Liu; Chandra C Ghosh; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2019-09-18       Impact factor: 3.575

8.  C/EBPβ and Nuclear Factor of Activated T Cells Differentially Regulate Adamts-1 Induction by Stimuli Associated with Vascular Remodeling.

Authors:  Jorge Oller; Arántzazu Alfranca; Nerea Méndez-Barbero; Silvia Villahoz; Noelia Lozano-Vidal; Mara Martín-Alonso; Alicia G Arroyo; Amelia Escolano; Angel Luis Armesilla; Miguel R Campanero; Juan Miguel Redondo
Journal:  Mol Cell Biol       Date:  2015-07-27       Impact factor: 4.272

Review 9.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

Review 10.  Multiple functions of HuR in urinary tumors.

Authors:  Fa Zhang; Zhonglin Cai; Haidi Lv; Wenjuan Li; Mengtian Liang; Xupan Wei; Fenghai Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.